Aktie·LSE·£
Illumina, Inc. specializes in delivering advanced sequencing and array technologies designed for genetic and genomic examination. These offerings cater to a diverse array of markets, fostering the widespread use of genomic insights across both research laboratories and clinical environments. Key application areas include life sciences, cancer diagnostics, reproductive medicine, agricultural science, and various nascent fields. The company's portfolio encompasses specialized instrumentation and associated consumables vital for genetic analysis. Additionally, it offers comprehensive genotyping and sequencing services, extends instrument maintenance contracts, and engages in development and licensing partnerships, alongside providing cancer screening services. Illumina's client base is extensive, comprising genomic research facilities, universities, state-funded laboratories, and healthcare providers. It also serves pharmaceutical firms, biotechnology companies, commercial molecular diagnostics providers, and businesses focused on consumer genomics. Globally, Illumina distributes its products through direct sales channels in North America, Europe, Latin America, and the Asia-Pacific. Furthermore, it leverages third-party life-science distributors to reach markets across Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Sehen Sie den Preis von 0J8Z.L live auf Ihrem physischen Bildschirm. Alarme via iOS- und Android-App.
